{
"METABOLOMICS WORKBENCH":{"STUDY_ID":"ST003042","ANALYSIS_ID":"AN004991","VERSION":"1","CREATED_ON":"01-16-2024"},

"PROJECT":{"PROJECT_TITLE":"The metabolomic resetting effect of DY131 in cisplatin-induced AKI","PROJECT_TYPE":"MS quantitative analysis","PROJECT_SUMMARY":"Acute kidney injury (AKI) remains a challenge in clinical practice, and mitochondrial injury is a hallmark of AKI independent of the exact aetiology. ERRγ is a member of orphan nuclear receptors which plays a regulatory role in mitochondrial biosynthesis, energy metabolism, oxidative stress, cell apoptosis, inflammation, and especially metabolic pathways. Here we investigate the role of pharmacological agonist of ERRγ, DY131, in AKI mice induced by cisplatin, IR and LPS. DY131 ameliorated renal function, tubular injury, cell apoptosis and inflammation in AKI mice with multiple causes. Furthermore, we performed LC-MS/MS analyses using renal tissues from cisplatin-induced AKI mice with or without DY131 treatment. Strikingly, the data revealed that DY131 alleviated cisplatin-induced mitochondrial dysfunction and energy metabolism disorder, as well as multiple metabolic disorders. Taken together, the findings highlighted the protective effect of DY131 on AKI probably via improving mitochondrial function and energy metabolism.","INSTITUTE":"Children's Hospital of Nanjing Medical University","DEPARTMENT":"Department of Nephrology, State Key Laboratory of Reproductive Medicine","LABORATORY":"Nanjing Key Lab of Pediatrics, Jiangsu Key Laboratory of Pediatrics","LAST_NAME":"Lu","FIRST_NAME":"Lingling","ADDRESS":"Guangzhou Road 72, Nanjing, Jiangsu, 210000, China","EMAIL":"lulingling89tara@163.com","PHONE":"0086-25-8311-7435","DOI":"http://dx.doi.org/10.21228/M81F0P"},

"STUDY":{"STUDY_TITLE":"The metabolomic resetting effect of DY131 in cisplatin-induced AKI","STUDY_TYPE":"MS","STUDY_SUMMARY":"LC-MS/MS analyses were performed using renal tissues from cisplatin-induced AKI mice with or without DY131 treatment. The data revealed that DY131 alleviated cisplatin-induced mitochondrial dysfunction and energy metabolism disorder, as well as multiple metabolic disorders.","INSTITUTE":"Children's Hospital of Nanjing Medical University","DEPARTMENT":"Department of Nephrology, State Key Laboratory of Reproductive Medicine","LABORATORY":"Nanjing Key Lab of Pediatrics, Jiangsu Key Laboratory of Pediatrics","LAST_NAME":"Lu","FIRST_NAME":"Lingling","ADDRESS":"Guangzhou Road 72, Nanjing, Jiangsu, 210000, China","EMAIL":"lulingling89tara@163.com","PHONE":"0086-25-8311-7435","SUBMIT_DATE":"2023-12-21"},

"SUBJECT":{"SUBJECT_TYPE":"Mammal","SUBJECT_SPECIES":"Mus musculus","TAXONOMY_ID":"10090","GENOTYPE_STRAIN":"C57BL/6J","AGE_OR_AGE_RANGE":"7-8 weeks","WEIGHT_OR_WEIGHT_RANGE":"20-25g","GENDER":"Male","ANIMAL_ANIMAL_SUPPLIER":"Nanjing Medical University","ANIMAL_HOUSING":"Nanjing Medical University","ANIMAL_FEED":"Free to food","ANIMAL_WATER":"Free to clean water"},
"SUBJECT_SAMPLE_FACTORS":[
{
"Subject ID":"-",
"Sample ID":"C_1",
"Factors":{"Treatment":"control"},
"Additional sample data":{"RAW_FILE_NAME":"pos_C_1.mzXML","RAW_FILE_NAME":"neg_C_1.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"C_2",
"Factors":{"Treatment":"control"},
"Additional sample data":{"RAW_FILE_NAME":"pos_C_2.mzXML","RAW_FILE_NAME":"neg_C_2.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"C_3",
"Factors":{"Treatment":"control"},
"Additional sample data":{"RAW_FILE_NAME":"pos_C_3.mzXML","RAW_FILE_NAME":"neg_C_3.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"C_4",
"Factors":{"Treatment":"control"},
"Additional sample data":{"RAW_FILE_NAME":"pos_C_4.mzXML","RAW_FILE_NAME":"neg_C_4.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"C_5",
"Factors":{"Treatment":"control"},
"Additional sample data":{"RAW_FILE_NAME":"pos_C_5.mzXML","RAW_FILE_NAME":"neg_C_5.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"C_6",
"Factors":{"Treatment":"control"},
"Additional sample data":{"RAW_FILE_NAME":"pos_C_6.mzXML","RAW_FILE_NAME":"neg_C_6.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"C_7",
"Factors":{"Treatment":"control"},
"Additional sample data":{"RAW_FILE_NAME":"pos_C_7.mzXML","RAW_FILE_NAME":"neg_C_7.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"DY_P_1",
"Factors":{"Treatment":"DY131+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_DP_1.mzXML","RAW_FILE_NAME":"neg_DP_1.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"DY_P_2",
"Factors":{"Treatment":"DY131+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_DP_2.mzXML","RAW_FILE_NAME":"neg_DP_2.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"DY_P_3",
"Factors":{"Treatment":"DY131+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_DP_3.mzXML","RAW_FILE_NAME":"neg_DP_3.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"DY_P_4",
"Factors":{"Treatment":"DY131+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_DP_4.mzXML","RAW_FILE_NAME":"neg_DP_4.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"DY_P_5",
"Factors":{"Treatment":"DY131+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_DP_5.mzXML","RAW_FILE_NAME":"neg_DP_5.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"DY_P_6",
"Factors":{"Treatment":"DY131+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_DP_6.mzXML","RAW_FILE_NAME":"neg_DP_6.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"DY_P_7",
"Factors":{"Treatment":"DY131+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_DP_7.mzXML","RAW_FILE_NAME":"neg_DP_7.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"P_1",
"Factors":{"Treatment":"vehicle+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_P_1.mzXML","RAW_FILE_NAME":"neg_P_1.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"P_2",
"Factors":{"Treatment":"vehicle+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_P_2.mzXML","RAW_FILE_NAME":"neg_P_2.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"P_3",
"Factors":{"Treatment":"vehicle+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_P_3.mzXML","RAW_FILE_NAME":"neg_P_3.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"P_4",
"Factors":{"Treatment":"vehicle+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_P_4.mzXML","RAW_FILE_NAME":"neg_P_4.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"P_5",
"Factors":{"Treatment":"vehicle+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_P_5.mzXML","RAW_FILE_NAME":"neg_P_5.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"P_6",
"Factors":{"Treatment":"vehicle+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_P_6.mzXML","RAW_FILE_NAME":"neg_P_6.mzXML"}
},
{
"Subject ID":"-",
"Sample ID":"P_7",
"Factors":{"Treatment":"vehicle+cisplatin"},
"Additional sample data":{"RAW_FILE_NAME":"pos_P_7.mzXML","RAW_FILE_NAME":"neg_P_7.mzXML"}
}
],
"COLLECTION":{"COLLECTION_SUMMARY":"The mice were euthanized 72 hours after cisplatin injection, and renal tissues were collected and frozen at -80℃.","SAMPLE_TYPE":"Kidney","STORAGE_CONDITIONS":"-80℃"},

"TREATMENT":{"TREATMENT_SUMMARY":"Wild type C57BL/6J mice were maintained under standard environmental conditions. A single injection of cisplatin (25 mg/kg, i.p.) was used to induce AKI. DY131 was dissolved in DMSO and further diluted with 5% Tween-80. To assess the effect of DY131, the mice were injected with DY131 (5 mg/kg, i.p.) or vehicle one hour before cisplatin injection, repeated every 24 hours. The mice were euthanized 72 hours after cisplatin injection.","TREATMENT_COMPOUND":"cisplatin or saline, DY131 or vehicle","TREATMENT_ROUTE":"intraperitoneal injection ​","TREATMENT_DOSE":"cisplatin at 25 mg/kg, once. DY131 at 5 mg/kg, once a day for 3 days","TREATMENT_DOSEVOLUME":"Animal Vet Treatments:  Animal Anesthesia:  Animal Acclimation Duration:  Animal Fasting:  Animal Endpoint Euthanasia:  Animal Endpoint Tissue Coll. List:  Animal Endpoint Tissue Proc. Method:  Animal Endpoint Clinical Signs:","TREATMENT_VEHICLE":"cisplatin dissolved in saline, DY131 dissolved in DMSO and further diluted with 5% Tween-80"},

"SAMPLEPREP":{"SAMPLEPREP_SUMMARY":"25 mg of sample was weighted to an EP tube, and 500 μL extract solution (acetonitrile: methanol: water = 2: 2: 1, with isotopically-labelled internal standard mixture) was added. After 30 s vortex, the samples were homogenized at 35 Hz for 4 min and sonicated for 5 min in ice-water bath. The homogenization and sonication cycle was repeated for 3 times. Then the samples were incubated for 1 h at -40 ℃ and centrifuged at 12000 rpm for 15 min at 4 ℃. The resulting supernatant was transferred to a fresh glass vial for analysis."},

"CHROMATOGRAPHY":{"METHODS_FILENAME":"DY131_Chromatography.txt","INSTRUMENT_NAME":"Thermo Fisher Scientific","COLUMN_NAME":"Waters ACQUITY UPLC BEH Amide (100 x 2.1mm,1.7um)","COLUMN_TEMPERATURE":"30 ℃","FLOW_GRADIENT":"0-0.5min, 95% B; 0.5-7min, 95%-65%B; 7-8min, 65%B-40%B; 8-9min, 40%B; 9-9.1min, 40%-95%B; 9.1-12min, 95%B","FLOW_RATE":"0.5ml/min","SOLVENT_A":"water（pH = 9.75)","SOLVENT_B":"acetonitrile","CHROMATOGRAPHY_TYPE":"HILIC"},

"ANALYSIS":{"ANALYSIS_TYPE":"MS","ANALYSIS_PROTOCOL_FILE":"DY131_MS.txt"},

"MS":{"INSTRUMENT_NAME":"Thermo Q Exactive HF-X Orbitrap","INSTRUMENT_TYPE":"Orbitrap","MS_TYPE":"ESI","MS_COMMENTS":"sheath gas flow rate as 30 Arb, Aux gas flow rate as 25 Arb, capillary temperature 350 ℃, full MS resolution as 60000, MS/MS resolution as 7500, collision energy as 10/30/60 in NCE mode, spray Voltage as -3.2 kV (negative). Metabolites were quantified by relative quantification and expressed by peak area.","ION_MODE":"NEGATIVE","MS_RESULTS_FILE":"ST003042_AN004991_Results.txt UNITS:Peak area Has m/z:Yes Has RT:Yes RT units:Minutes"}

}